Immunological changes in psoriasis patients under long-term treatment with fumaric acid esters: Risk of Kaposi sarcoma occurrence?

European Journal of Dermatology

Volumn 23, Issue 3, 2013, Pages 339-343

  Philipp, Sandra ^a   Kokolakis, Georgios ^a   Hund, Martina ^a   Witte, Ellen ^a   Witte, Katrin ^a   Kunz, Stefanie ^a   Roewert, Hans Joachim ^a   Sterry, Wolfram ^a   Sabat, Robert ^a  

^a CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

Author keywords

Fumaric acid esters; HHV 8; Kaposi sarcoma; Psoriasis; T cells

Indexed keywords

FUMARIC ACID; METHOTREXATE; RETINOID; FUMARIC ACID DERIVATIVE;

ADULT; ARTICLE; BLOOD ANALYSIS; BLOOD CELL COUNT; CD4 CD8 RATIO; CD4 LYMPHOCYTE COUNT; CD8+ T LYMPHOCYTE; CELL COUNT; CLINICAL ARTICLE; HISTOLOGY; HUMAN; HUMAN HERPESVIRUS 8; HUMAN TISSUE; IMMUNE RESPONSE; INFECTION RISK; KAPOSI SARCOMA; LATENT VIRUS INFECTION; LEUKOCYTE COUNT; LONG TERM CARE; LYMPHOCYTE COUNT; LYMPHOCYTOPENIA; MALE; NATURAL KILLER CELL; PREVALENCE; PSORIASIS; PUNCH BIOPSY; SEROLOGY; TREATMENT DURATION; TREATMENT OUTCOME; ULTRAVIOLET B RADIATION; VIRUS DETECTION; CASE REPORT; IMMUNOLOGY; MIDDLE AGED; RISK FACTOR; SARCOMA, KAPOSI; SKIN NEOPLASMS; TIME; VIROLOGY;

FUMARATES; HERPESVIRUS 8, HUMAN; HUMANS; MALE; MIDDLE AGED; PSORIASIS; RISK FACTORS; SARCOMA, KAPOSI; SKIN NEOPLASMS; TIME FACTORS;

EID: 84880646315     PISSN: 11671122     EISSN: 19524013     Source Type: Journal    
DOI: 10.1684/ejd.2013.2014     Document Type: Article

References (19)

1. Griffiths CE, Barker JN. Pathogenesis and clinical features of psoriasis. Lancet 2007; 370(9583): 263-71.
2. Sabat R, Philipp S, Hoflich C, et al. Immunopathogenesis of psoriasis. Exp Dermatol 2007; 16: 779-98.
3. Mrowietz U, Altmeyer P, Bieber T, Rocken M, Schopf RE, Sterry W. Treatment of psoriasis with fumaric acid esters (Fumaderm). J Dtsch Dermatol Ges 2007; 5: 716-7.
4. Reich K, Thaci D, Mrowietz U, Kamps A, Neureither M, Luger T. Efficacy and safety of fumaric acid esters in the long-term treatment of psoriasis-a retrospective study (FUTURE). J Dtsch Dermatol Ges 2009; 7: 603-11.
5. Brewer L, Rogers S. Fumaric acid esters in the management of severe psoriasis. Clin Exp Dermatol 2007; 32: 246-9.
6. Naldi L, Griffiths CE. Traditional therapies in the management of moderate to severe chronic plaque psoriasis: an assessment of the benefits and risks. Br J Dermatol 2005; 152: 597-615.
7. Hengge UR, Ruzicka T, Tyring SK, et al. Update on Kaposi's sarcoma and other HHV8 associated diseases. Part 2: pathogenesis, Castleman's disease, and pleural effusion lymphoma. Lancet Infect Dis 2002; 2: 344-52.
8. Horenstein MG, Moontasri NJ, Cesarman E. The pathobiology of Kaposi's sarcoma: advances since the onset of the AIDS epidemic. J Cutan Pathol 2008; 35 Suppl 2: 40-4.
9. Wolk K, Docke WD, von Baehr V, Volk HD, Sabat R. Impaired antigen presentation by human monocytes during endotoxin tolerance. Blood 2000; 96: 218-23.
10. Salgo R, Thaci D, Boehncke S, Diehl S, Hofmann M, Boehncke WH. Microdialysis documents changes in the micromilieu of psoriatic plaques under continuous systemic therapy. Exp Dermatol 2011; 20: 130-3.
11. Litjens NH, Nibbering PH, Barrois AJ, et al. Beneficial effects of fumarate therapy in psoriasis vulgaris patients coincide with downregulation of type 1 cytokines. Br J Dermatol 2003; 148: 444-51.
12. Hoxtermann S, Nuchel C, Altmeyer P. Fumaric acid esters suppress peripheral CD4-and CD8-positive lymphocytes in psoriasis. Dermatology 1998; 196: 223-30.
13. Kempf W, Perniciaro C, Adams V, Mueller B, Burg G. Human herpesvirus 8 (HHV-8) in familial Kaposi's sarcoma. Exp Dermatol 1999; 8: 68-70.
14. Viejo-Borbolla A, Schulz TF. Kaposi's sarcoma-associated herpesvirus (KSHV/HHV8): key aspects of epidemiology and pathogenesis. AIDS Rev 2003; 5: 222-9.
15. Haverkos HW. Multifactorial etiology of Kaposi' sarcoma: a hypothesis. J Biosc 2008; 33: 643-51.
16. Jones JL, Hanson DL, Dworkin MS, et al. Surveillance for AIDSdefining opportunistic illnesses, 1992-1997. MMWR CDC Surveill Summ 1999; 48: 1-22.
17. Rostami Yazdi M, Mrowietz U. Fumaric acid esters. Clin Dermatol 2008; 26: 522-6.
18. Rudek MA, Flexner C, Ambinder RF. Use of antineoplastic agents in patients with cancer who have HIV/AIDS. Lancet Oncol 2011; 12: 905-12.
19. Barth D, Simon JC, Wetzig T. Malignant melanoma during treatment with fumaric acid esters-coincidence or treatment-related? J Dtsch Dermatol Ges 2011; 9: 223-5.